Ruthigen to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City

SANTA ROSA, Calif., Sept. 4, 2014 /PRNewswire/ -- Ruthigen, Inc., (NASDAQ: RTGN) a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, today announced that the Company is scheduled to present at the Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10, 2014 at 2:30 p.m. ET.  The conference will be held at the New York Palace Hotel in New York City.

A live webcast of Ruthigen's presentation may be available at the following website: http://wsw.com/webcast/rrshq24/rtgn.  After the presentation, a replay will be archived and accessible for 90 days at the same website.

About Ruthigen
Ruthigen is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications.  The Company's lead drug candidate, RUT58-60, is a broad-spectrum anti-infective containing a new formulation of hypochlorous acid, HOCl, with small molecule stabilizers that Ruthigen is developing for the prevention and treatment of infection in surgical and trauma procedures.  RUT58-60 uses a mechanism of action designed to prevent emergence of bacterial resistance and improves patient safety by neither targeting specific bacterial cell membrane receptors nor exposing patient's vital organs to unnecessary systemic drugs.  The Company plans to complete its Phase I/II clinical trial in Q1 2015 and pending the successful completion of that trial, Ruthigen plans to conduct pivotal clinical trials.  The Company's clinical program targets an initial $700M potential market in the prevention of infections associated with abdominal surgery.  The Company believes the market for prevention of infection in the U.S. surgical market is estimated at $3B.  For more information, visit www.ruthigen.com.

SOURCE Ruthigen, Inc.